Article
Oncology
Josef Vymazal, Tomas Kazda, Tomas Novak, Petr Slanina, Jan Sroubek, Jan Klener, Tomas Hrbac, Martin Syrucek, Aaron M. M. Rulseh
Summary: This study evaluated the efficacy of TTFields therapy in newly-diagnosed glioblastoma patients and found that it improved progression-free survival and overall survival compared to control patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Jethro L. Hu, Oluwaseun A. Omofoye, Jeremy D. Rudnick, Sungjin Kim, Mourad Tighiouart, Surasak Phuphanich, Hongqiang Wang, Mia Mazer, Toni Ganaway, Ray M. Chu, Chirag G. Patil, Keith L. Black, Stephen L. Shiao, Rongfu Wang, John S. Yu
Summary: The study used an autologous dendritic cell vaccine pulsed with lysate from a GBM stem-like cell line for treating newly diagnosed and recurrent GBM, showing that the treatment was safe and well tolerated. Some patients developed a cytotoxic T-cell response, suggesting the potential role of immunotherapy in the treatment of GBM.
CLINICAL CANCER RESEARCH
(2022)
Review
Medicine, Research & Experimental
Shiyu Liu, Weiyan Shi, Qin Zhao, Zhuangzhuang Zheng, Zijing Liu, Lingbin Meng, Lihua Dong, Xin Jiang
Summary: TTFields is a treatment technology that induces apoptosis of cancer cells by generating an electric field, and is promising for the treatment of glioblastoma with few side effects.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Oncology
Martin Glas, Matthew T. Ballo, Ze'ev Bomzon, Noa Urman, Shay Levi, Gitit Lavy-Shahaf, Suriya Jeyapalan, Terence T. Sio, Paul M. DeRose, Martin Misch, Sophie Taillibert, Zvi Ram, Andreas F. Hottinger, Jacob Easaw, Chae-Yong Kim, Suyash Mohan, Roger Stupp
Summary: TTFields treatment affects the rate of distant progression in newly diagnosed GBM patients, with distant lesions appearing further from the primary lesion in the TTFields treatment arm. Distant progression correlates with improved clinical outcomes in TTFields patients.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Review
Oncology
Katarzyna Szklener, Mateusz Bilski, Karolina Nieoczym, Dominika Mandziuk, Slawomir Mandziuk
Summary: Glioblastoma is an aggressive and difficult-to-treat tumor. Tumor Treating Fields can disrupt its growth through various mechanisms, and combining them with chemotherapy, radiotherapy, and immunotherapy may result in synergistic effects. This treatment has minimal side effects and does not pose significant barriers to combination therapies.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Antonio Dono, Sonali Mitra, Mauli Shah, Takeshi Takayasu, Jay-Jiguang Zhu, Nitin Tandon, Chirag B. Patel, Yoshua Esquenazi, Leomar Y. Ballester
Summary: This retrospective study analyzed data from 530 patients with infiltrating gliomas and found that TTFields therapy conferred significant survival benefits in PTEN-mutant rGBM patients, optimizing the application of this treatment option. Understanding the molecular mechanisms behind the differences in response to TTFields therapy can help tailor treatment plans for patients more effectively.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Article
Oncology
Na Tosha N. Gatson, Jill Barnholtz-Sloan, Jan Drappatz, Roger Henriksson, Andreas F. Hottinger, Piet Hinoul, Carol Kruchko, Vinay K. Puduvalli, David D. Tran, Eric T. Wong, Martin Glas
Summary: The COVID-19 pandemic has posed challenges to the healthcare system, particularly in treatment decision-making for cancer patients. Experts discussed the risk-to-benefit ratio of using TTFields in GBM patients during the pandemic, emphasizing the importance of this treatment during the crisis, especially for elderly patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Won Seok Lee, Seung-Jun Seo, Hye Kyung Chung, Jang Woo Park, Jong-Ki Kim, Eun Ho Kim
Summary: The combination of TTFields therapy and proton radiation has shown a significant anticancer impact on GBM, curbing cell migration and downregulating key signaling pathways. This combination provides biological evidence for the molecular basis of TTFields and proton therapy in treating GBM.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Oncology
Henry S. Friedman, Michael D. Prados, Patrick Y. Wen, Tom Mikkelsen, David Schiff, Lauren E. Abrey, W. K. Alfred Yung, Nina Paleologos, Martin K. Nicholas, Randy Jensen, James Vredenburgh, Jane Huang, Maoxia Zheng, Timothy Cloughesy
Summary: This study evaluated the efficacy of bevacizumab, alone or in combination with irinotecan, in recurrent glioblastoma patients. The results showed that bevacizumab, either alone or in combination, was well tolerated and active in treating recurrent glioblastoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Cell Biology
Amber B. Jones, Taylor L. Schanel, Mikayla R. Rigsby, Corinne E. Griguer, Braden C. Mcfarland, Joshua C. Anderson, Christopher D. Willey, Anita B. Hjelmeland
Summary: Treatment for glioblastoma has been improved through the non-invasive addition of tumor treating fields (TTFields). TTFields decrease the growth of glioblastoma cells and may have therapy-specific vulnerabilities. The activity of PDGFR alpha may serve as a pro-survival mechanism for TTFields.
Article
Clinical Neurology
Lei She, Xuan Gong, Lin Su, Chao Liu
Summary: This study aimed to evaluate the clinical efficacy and safety of TTFields therapy for glioblastoma (GBM) in China. The results showed that TTFields treatment improved progression-free survival (PFS) in newly diagnosed GBM patients, especially in those with subtotal resection. However, TTFields therapy did not improve survival outcomes in recurrent GBM patients.
FRONTIERS IN NEUROLOGY
(2023)
Article
Medicine, Research & Experimental
Dongjiang Chen, Son B. Le, Tarun E. Hutchinson, Anda-Alexandra Calinescu, Mathew Sebastian, Dan Jin, Tianyi Liu, Ashley Ghiaseddin, Maryam Rahman, David D. Tran
Summary: TTFields, a novel therapy for GBM and other solid tumors, disrupts mitotic spindle and induces inflammation to exert its anti-tumor effects. The study reveals that TTFields can activate DNA sensors and inflammasomes to produce immune response, leading to antitumor immunity and cure.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Review
Clinical Neurology
Xiaohui Li, Zetian Jia, Yaqi Yan
Summary: TTF therapy is effective for recurrent glioblastoma and the baseline characteristics of patients and the risk of device-related rashes should be considered.
ACTA NEUROCHIRURGICA
(2022)
Article
Pharmacology & Pharmacy
Hong-Hong Zhang, Xiao-Jing Du, Mei-Ling Deng, Lie Zheng, Dun-Chen Yao, Zhi-Qiang Wang, Qun-Ying Yang, Shao-Xiong Wu
Summary: This study retrospectively evaluated the efficacy and safety of apatinib in recurrent/progressive GBM patients. The results showed that apatinib therapy provided a better salvaging option for recurrent/progressive GBM patients and the toxicity was manageable.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Xiaopeng Guo, Xin Yang, Jiaming Wu, Huiyu Yang, Yilin Li, Junlin Li, Qianshu Liu, Chen Wu, Hao Xing, Penghao Liu, Yu Wang, Chunhua Hu, Wenbin Ma
Summary: Glioblastoma (GBM) is a common malignant primary brain tumor with a low 5-year survival rate. Tumor-treating fields (TTFields) have emerged as the fourth most effective treatment option for GBMs, prolonging patient survival and showing acceptable adverse events. TTFields disrupts cell mitosis, delays DNA repair, enhances autophagy, inhibits cell metabolism and angiogenesis, and limits cancer cell migration. It also strengthens antitumor immunity, increases cell membrane and blood-brain barrier permeability, and disrupts DNA-damage-repair processes. However, the overall acceptance of TTFields in clinical practice is still low. This review provides an updated understanding of the mechanism of action, efficacy, safety, clinical concerns, and future perspectives of TTFields in GBMs.
Article
Radiology, Nuclear Medicine & Medical Imaging
Alberto Malucelli, Antonin Skoch, Svapotluk Ostry, Ales Tomek, Barbora Urbanova, Lukas Martinkovic, Irena Buksakowska, Milan Mohapl, David Netuka, Jakub Hort, Jan Sroubek, Jiri Vrana, Tomas Moravec, Robert Bartos, Martin Sames, Milan Hajek, Daniel Horinek
Summary: Patients with unilateral occlusion of the internal carotid artery demonstrate altered cerebral metabolism and anatomy, with lower NAA/Cho ratio and reduced hippocampal volume. These changes cannot be solely explained by alterations in hemodynamics.
MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE
(2021)
Article
Neurosciences
Jan Sroubek, Ladislava Janouskova, Jan Klener
Article
Cardiac & Cardiovascular Systems
Pavel Hala, Petr Neuzil, Jiri Keller, Petr Moucka, Martin Mudroch, Libor Dujka, Marek Janotka, Radovan Zacek, Josef Vymazal, Vivek Reddy
Summary: This study demonstrated that implantation of leadless pacemaker causes image distortion mainly in the septal, inferoseptal, and anteroseptal segments of apical and midventricular LV myocardium. However, the impact is minimal on the basal and lateral segments. The image distortion is more significant in systole compared to diastole, except for the apex.
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY
(2021)
Article
Medicine, Research & Experimental
Ivana Stetkarova, Lenka Kramska, Jiri Keller
Summary: Long-term administration of ITB did not lead to significant decline in memory functions in SCI subjects, but rather resulted in a significant improvement in short-term auditory-verbal memory and logical memory performance.
Article
Clinical Neurology
Jiri Keller, Anna Kavkova, Radoslav Matej, Zsolt Csefalvay, Robert Rusina
Summary: The study found that GGT type I patients exhibit specific MRI abnormalities including a sagittal callosal hyperintense band, callosal atrophy, periventricular white matter lesions, and brain stem atrophy. These MRI findings are common in patients with atypical dementia, parkinsonism, and late incomplete supranuclear gaze palsy.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Review
Biochemistry & Molecular Biology
Jana Amlerova, Jan Sroubek, Francesco Angelucci, Jakub Hort
Summary: Epilepsy is a chronic neurological disorder characterized by unprovoked seizures, with a potential relationship to gut microbiota dysbiosis. Restoring gut microbiota balance may improve epilepsy symptoms and increase the effectiveness of treatment drugs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Letter
Clinical Neurology
Jiri Taborsky, Radoslav Matej, Hana Vlaskova, Jiri Keller, Silvie Johanidesova, Robert Rusina
NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Ivana Stetkarova, Edvard Ehler, Michal Zido, David Lauer, Jan Polak, Jiri Keller, Tomas Peisker
Summary: Hyperglycaemia and elevated CRP are relatively common in patients with Guillain-Barre syndrome (GBS) during the acute phase of admission and may be associated with the severity of GBS.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Ivana Stetkarova, Jiri Keller
Summary: This study investigated the effects of intrathecal baclofen (ITB) treatment on cortical activation in patients with spinal cord injury (SCI) using functional magnetic resonance imaging (fMRI). The results showed that continuous ITB treatment reduced limb spasticity and increased activation in the primary sensorimotor cortex of the foot. This increased activation may reflect functional reorganization in the brain.
FRONTIERS IN NEUROLOGY
(2022)
Article
Biochemistry & Molecular Biology
Nikol Jankovska, Robert Rusina, Jiri Keller, Jaromir Kukal, Magdalena Bruzova, Eva Parobkova, Tomas Olejar, Radoslav Matej
Summary: This retrospective study examined correlations of clinical, neuropathological, molecular-genetic, immunological, and neuroimaging biomarkers in pure and comorbid Creutzfeldt-Jakob disease (CJD). A surprisingly high proportion of comorbid neuropathologies were found, complicating the clinical diagnosis of CJD.
Article
Clinical Neurology
Robert Rusina, Radoslava Bajtosova, Zsolt Csefalvay, Jiri Keller, Anna Kavkova, Jaromir Kukal, Radoslav Matej
Summary: Primary progressive aphasia (PPA) is a progressive syndrome characterized by the loss of speech and language. This study suggests that the etiology of PPA is more heterogeneous than previously thought, with multiple neurodegenerative comorbidities being common. It emphasizes the importance of considering underlying neurodegenerative pathologies, especially in cases with atypical clinical presentations.
BEHAVIOURAL NEUROLOGY
(2022)
Article
Neurosciences
Jiri Nepozitek, Zsoka Varga, Simona Dostalova, Pavla Perinova, Jiri Keller, Simon Robinson, Veronika Ibarburu, Iva Prihodova, Ondrej Bezdicek, Evzen Ruzicka, Karel Sonka, Petr Dusek
Summary: REM sleep without atonia (RWA) is a characteristic of isolated REM sleep behavior disorder (iRBD) caused by brainstem neurodegeneration. This study used quantitative susceptibility mapping (QSM) to compare brainstem magnetic susceptibility (MS) between iRBD patients and controls. The results showed higher MS in bilateral substantia nigra, red nucleus, and ventral tegmental area in the iRBD group. There was also a positive correlation between MS and iRBD duration in specific brainstem regions, as well as with phasic RWA in bilateral substantia nigra. These findings suggest that increased iron content in the substantia nigra may be related to RWA severity.
NPJ PARKINSONS DISEASE
(2023)
Meeting Abstract
Clinical Neurology
Petra Runa Vochozkova, Hannah Auch, Kateryna Nemesh, The Duong Nyguen, David Sekac, Eva Kamenna, Monika Baxa, Jiri Klima, Taras Ardan, Stefan Juhas, Bozena Levinska, Jana Juhasova, Jiri Keller, Jiri Klempir, Jan Motlik, Nikolai Klymiuk, Zdenka Ellederova
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Meeting Abstract
Clinical Neurology
I. Stetkarova, E. Ehler, M. Zido, D. Lauer, J. Polak, J. Keller, T. Peisker
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Meeting Abstract
Oncology
Aaron Rulseh, Adam Derner, Jan Sroubek, Jan Klener, Josef Vymazal